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Abstract
Obtaining drugs for use in basic and preclinical research has become increasingly diﬃcult and in many
instances is dependent upon the company’s interest in the proposed research. In this paper, we describe
a simple procedure for extracting the antidepressants sertraline, paroxetine, ﬂuoxetine, venlafaxine,
citalopram, escitalopram, duloxetine and atomoxetine from their readily available pharmaceutical
preparations. With the exception of citalopram, escitalopram and duloxetine in which the free base was
the ﬁnal product, the hydrochloride salt forms of these drugs were prepared. This procedure provides
these antidepressants in gram quantities in recovered yields ranging from 53% to 100% at over 99% purity
and is in principle applicable to other drugs as well.
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Introduction
The availability of antidepressant drugs in gram or
multi-gram quantities is necessary for basic investi-
gations of their pharmacology, particularly in studies
requiring large numbers of animals with long-term
drug administration. Of themodern, non-tricyclic anti-
depressants that are monoamine transporter antag-
onists, only ﬂuoxetine HCl is available for purchase ;
however, its current (May 2006) cost is $239 per 50 mg
(www.SigmaRBI.com). No other selective serotonin
reuptake inhibitor (SSRI) or serotonin/norepinephrine
reuptake inhibitor (SNRI) are available except directly
from the parent pharmaceutical companies. Upon
written request, these compounds may or may not be
provided directly to the investigator for use in dis-
crete, approved animal experiments following review
by the company. In contrast, the commercial pharma-
ceutical formulations of these same drugs are widely
available, used routinely for clinical indications and
are substantially less expensive on a dollar per gram
basis. In an era of growing concern over the potential
conﬂicts of interest between individual investigators
and the pharmaceutical industry, lower cost alterna-
tives and greater availability of these research tools
are needed. Because of the large price diﬀerential and
the refusal of requests to provide drugs for certain
experiments, we became interested in using the com-
mercial formulations of a number of antidepressants
as a source for use in our animal research projects.
The primary obstacle to using the pharmaceutical
formulations of these drugs is the large amount of
vehicle and inert material which interfere with precise
dosing and prevent dissolving the drugs in aqueous or
other suitable media for injection or osmotic mini-
pump administration. To obtain medications in a
suitable form for our research programme, we devel-
oped an organic extraction method for obtaining
paroxetine, sertraline, venlafaxine, ﬂuoxetine, citalo-
pram, escitalopram, duloxetine and atomoxetine
from their commercially available drug formulations.
This paper describes a simple method for extracting
and reformulating these antidepressants as well as
demonstrating their analytical purity.
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Materials and methods
All of the equipment, solvents and chemicals used for
the drug extractions are available from commercial
sources. Glassware as well as solvents for extraction
and chromatography were obtained from VWR
(West Chester, PA, USA). Chemicals were obtained
from Aldrich Chemicals (Milwaukee, WI, USA). Thin
layer chromatography (TLC) was performed using
250 mm layers of F-254 silica on aluminium plates
obtained from Whatman (Clifton, NJ, USA). 1H NMR
spectra were recorded using a Varian spectrometer
at 400 MHz. Elemental analyses were performed by
Atlanta Microlabs Inc. (Norcross, GA, USA). All of the
drugs used in the extraction were in their commer-
cially available pharmaceutical formulations (branded
and generic).
General procedure
The extractions and puriﬁcations should be performed
in a functioning fume hood designed for handling
volatile organic solvents. These procedures should
be carried out only by those familiar with the
safe handling of concentrated acids, bases and volatile
organic solvents. In particular, diethyl ether is
highly ﬂammable and can build up pressure during
extraction in separatory funnels. The techniques
summarized here are covered in detail in many
practical guides to organic chemistry (Vogel et al.,
1996).
The pharmaceutical formulation of the drug is
prepared for extraction by removing any readily
separable packaging such as capsules. For some drugs,
crushing the solid form such as tablets into a powder
form using a mortar and pestle can decrease the
time needed for drug extraction. This step may be
particularly important if sustained release formula-
tions are used. All of the antidepressants reported
here are weak bases. To convert the salt of the drug
in the pharmaceutical preparation into its free base
form, the drug is added to aqueous sodium hydroxide
(6 mM equivalents of sodium hydroxide per mmol
of drug in double-deionized water) using y75 ml of
NaOH solution per gram of drug in an Erlenmeyer
ﬂask. An equal volume of diethyl ether is added to the
ﬂask, and the two phases are stirred vigorously until
the solids are dissolved or pulverized into a ﬁne
powder. This stirring typically requires y15–20 min,
and the aqueous phase was pH 11 or higher at
this step.
The stirring is then stopped, and the two phases are
allowed to stand and separate. The organic phase
is then decanted into a separatory funnel (500 ml or
1000 ml), and any accompanying aqueous phase is
drained back into the Erlenmeyer ﬂask. The aqueous
phase is extracted with successive portions of organic
solvent until there is minimal residual drug in
the aqueous phase. During initial extractions, TLC
analysis with UV detection of successive extract was
performed to demonstrate adequate extraction of the
drug into the organic phase. A total of 2–3 organic
extractions removed the vast majority of the drugs
prepared using this method.
The organic extracts containing the drug are com-
bined in the separatory funnel and washed twice with
equal volumes of a saturated aqueous sodium chloride
solution to remove any residual water-soluble
material. The organic phase is then placed in a clean
Erlenmeyer ﬂask, and the residual water is removed
with anhydrous magnesium sulphate. This step is
performed by adding portions (typically 2–3 g) of
magnesium sulphate to the diethyl ether solution with
stirring until the magnesium sulphate powder stops
clumping. The magnesium sulphate is then removed
through vacuum ﬁltration using No. 2 Whatman ﬁlter
paper (Florham Park, NJ, USA). The organic solvent
is removed by rotary evaporation under reduced
pressure to provide the free base, typically as an oil.
Residual solvent is removed under a vacuum pump;
gentle heating (y40–50 xC) may assist in removal of
trace solvent. All drugs were stored in the dark. The
purity of the crude extract was evaluated by proton
NMR. For all the drugs described here, the proton
NMR spectra revealed that the free bases at this point
were suitable for conversion to their salt form or for
direct use in animal studies.
For all of the drugs except citalopram, escitalopram
and duloxetine, the free bases were readily converted
into a solid form as their hydrochloride (HCl) salts.
To prepare the HCl salt, the free base is dissolved
in the minimum amount of ethanol needed to obtain
a homogenous solution of the free base. If small
amounts of particulate matter are present, the ethanol
solution can be ﬁltered through a small cotton plug
in a Pasteur pipette pre-rinsed with ethanol. To
the ethanolic solution of the free base on ice, 2 M
equivalents of concentrated aqueous hydrochloric
acid are added dropwise with stirring. Depending
upon the drug, a crystalline solid or gel may form
at this point. For some drugs (see details below), the
crystalline solid can be isolated through vacuum
ﬁltration. In other cases, the solution can be con-
centrated with rotary evaporation under reduced
pressure to provide the HCl salt of the drug in a
solid form. Residual solvent can be removed with a
vacuum pump.
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The identity and purity of the ﬁnal drug product
was conﬁrmed by proton NMR and elemental analy-
sis. NMR was performed using deuterated chloroform
for free bases or deuterated water or methanol for the
salt form of the drugs. Drugs were considered pure
and suitable for use in experiments if the proton
NMR spectra corresponded to the spectra previously
reported in the literature (Basappa et al., 2004 ; Kamal
et al., 2002 ; Salsbury and Isbester, 2005) and the
elemental analyses were within 0.4% of the theoretical
values. Spectra for citalopram and duloxetine were not
found in the scientiﬁc literature (United States and
European patents only) but our proton NMR spectra
matched the predicted spectrum for these compounds
and are available upon request. The structures of the
drugs isolated using this procedure are depicted in
Figure 1.
Procedural details for speciﬁc drugs
Sertraline
Sertraline (Zoloft1, 25 or 50 mg tablets) preparation
can be performed using the general procedure with
formation of the HCl salt. The 1HNMR (CDCl3) can be
found in Salsbury and Isbester (2005). Elemental
analysis for sertraline HCl (C17H18Cl3N): Calculated
C: 59.58, H: 5.29, N: 4.09 ; Found C: 59.58, H: 5.26,
N: 4.08.
Paroxetine
Paroxetine (Paxil1 20 mg or Paxil CR1 25 mg
tablets) preparation is performed using the general
procedure with formation of the HCl salt. The
coloured ﬁlm coat of the tablets was scraped oﬀ
with a razor to avoid the need for ﬂash column
chromatography for puriﬁcation of the free base
extract. The HCl salt formation led to paroxetine HCl
hemihydrate (2 :1 molar ratio of paroxetine HCl
to water). The 1H NMR (CDCl3) can be found in
Salsbury and Isbester (2005). Elemental analysis
of paroxetine HCl hemihydrate (C38H44Cl2F2N2O7) :
Calculated C: 60.88, H: 5.92, N: 3.74 ; Found C: 60.91,
H: 5.98, N: 3.77.
Fluoxetine
Fluoxetine (generic ﬂuoxetine 20 mg capsules) prep-
aration is performed by emptying the drug from the
capsules. To avoid formation of a viscous suspension
during extraction, larger volumes of aqueous and
diethyl ether phases were used than in the routine
procedure (e.g. 2 g ﬂuoxetine per 350 ml of aqueous
sodium hydroxide and 350 ml of diethyl ether). The 1H
NMR (CDCl3) can be found in Kamal et al. (2002).
Elemental analysis for ﬂuoxetine HCl (C17H19ClF3NO):
Calculated C: 59.05, H: 5.54, N: 4.05 ; Found C: 59.02,
H: 5.62, N: 4.02.
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Figure 1. Antidepressants obtained from the extraction procedures.
Preparation of antidepressants 761
Venlafaxine
Venlafaxine (Eﬀexor XR1 75 mg capsules) was ex-
tracted using the general procedure with the exception
that the saturated NaCl solution was not added to
the original ether extract as this led to more diﬃcult
separation of the aqueous and organic fractions.
Formation of the HCl salt with immediate isolation
of the crystalline HCl salt via vacuum ﬁltration
leads to a more water soluble HCl salt form albeit
at a reduced overall yield compared with letting
the crystallization process proceed for several hours
in which a polymorphic salt formed that was less
soluble in aqueous solution. Both salt forms were
soluble in polyethylene glycol 400 :saline vehicles. The
1HNMR (CDCl3) can be found in Basappa et al. (2004).
Elemental analysis of venlafaxine HCl (C17H28ClNO2) :
Calculated C: 65.05, H: 8.99, N: 4.46 ; Found C: 65.00,
H: 8.98, N: 4.44.
Escitalopram and citalopram
Escitalopram (Lexapro1 10 mg tablets) and citalo-
pram (Celexa1 20 mg tablets) were extracted using
the general procedure. Free base preparation lead to
trace amounts of residual diethyl ether detectable
by 1H NMR. However, the percent contamination is
estimated at <1% by elemental analysis and proton
NMR. Elemental analysis for escitalopram free base
(C20H21FN2O): Calculated C: 74.05, H: 6.53, N: 8.64 ;
Found C: 74.14, H: 6.73, N: 8.57. We were unable to
obtain puriﬁed HCl salts using the simple procedure
outlined above and used the free base preparations in
our preclinical studies.
Duloxetine
Duloxetine (Cymbalta1 30 mg capsules) preparation
is performed using the general procedure. The starting
material is emptied from the capsules and ground
before extraction. Duloxetine undergoes some de-
composition under acidic conditions (Wheeler and
Kuo, 1995) and this was noted during the attempted
formation of the HCl salt. Duloxetine should be stored
in the dark. The free base was pure by 1H NMR
(CDCl3).
Atomoxetine
Atomoxetine (Strattera1 40 mg capsules) preparation
is performed using the general procedure with
formation of the HCl salt. The starting material
is emptied from the capsules prior to extraction.
The 1H NMR (CDCl3) can be found in Kamal et al.
(2002). Elemental analysis of atomoxetine HCl
(C17H22ClNO): Calculated C: 69.97, H: 7.60, N: 4.80 ;
Found C: 69.64, H: 7.69, N: 4.85.
Results and discussion
The methods described here provide a means for
obtaining analytically pure antidepressant drugs on a
gram scale from inexpensive, commercially available
pharmaceutical preparations. Combustion elemental
analysis and proton NMR demonstrated that the ﬁnal
products were at least 99% pure. With the exception
of citalopram, escitalopram and duloxetine, the HCl
salt of the antidepressants was prepared. The drugs
prepared using this method were suitable for use in
many types of preclinical experiments. This method
could be adapted to the extraction of other drugs not
described here.
The initial step in the procedure is conversion of
the pharmaceutical preparation (usually a salt) of the
drug into the free base (deprotonated, non-ionized
form) using sodium hydroxide. The organic extrac-
tions performed for each drug take advantage
of the fact that the only signiﬁcant component of
pharmaceutical preparations of these drugs that are
organic soluble under basic conditions are the drugs
themselves. The inert vehicle and other components
in the pharmaceutical formulations remain in the
aqueous phase or are insoluble. The organic extracts
containing the desired drug are washed with satu-
rated aqueous sodium chloride to remove residual
water-soluble contaminants. The small amount of
residual water in the diethyl ether organic phase is
removed with magnesium sulphate, and the organic
solvent is then removed to provide the free base of
the drug. For the drugs described here, the free bases
were analytically pure at this point. It is possible
that other drugs not described here could contain un-
desired organic-soluble material from their pharma-
ceutical formulations. These free bases could be
puriﬁed using ﬂash column chromatography which
is routinely used in synthetic organic chemistry and
is described in most laboratory organic chemistry
texts.
In principle, the free bases can be used for exper-
iments, but they are usually thick oils that are not
soluble in water without acid or a buﬀer and are
less easily handled than their solid HCl salt forms.
The HCl salts were prepared in part because hydro-
chloric acid is a gas at room temperature allowing easy
removal of the excess hydrochloric acid used in salt
formation. Other salts (e.g. oxalate, hydrobromide,
acetate) could be prepared from the free bases if
desired.
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The identity and purity of the products of these ex-
tractions were determined by proton NMR and com-
bustion analysis. Proton NMR is a standard method
for characterizing organic compounds, and each drug
has its own unique spectrum. The NMR spectra of the
extraction products were compared with the reported
spectra in the literature to demonstrate identity.
Proton NMR is also sensitive for detecting impurities
that contain protons. Combustion elemental analysis
is routinely used to determine the percentage of
the molecular weight of a compound contributed by
carbon (C), hydrogen (H) and nitrogen (N). The
theoretical values for C, H and N are compared with
the experimentally determined values, and the diﬀer-
ence between the two values should be less than
¡0.4%. When this condition is met and the proton
NMR spectrum demonstrates signals arising only
from the drug, the product is considered pure. Correct
elemental analysis is important for accurate drug
dosing as it ensures that 1 g of product from extraction
is 1 g of the drug and is not contaminated by
other material. For example, venlafaxine HCl has a
molecular formula of C17H28ClNO2, and the theoretical
percent of the mass of venlafaxine HCl due to carbon
is 65.05. With an experimental value of 65.00, the
estimated purity of the venlafaxine HCl is 99.92%
(calculated from 65.00/65.05r100%).
In the case of citalopram and escitalopram, the es-
timated purity based on proton NMR and elemental
analysis is over 99% despite trace diethyl ether.
It is extremely unlikely that the residual solvent
contamination of escitalopram or citalopram has any
pharmacological actions when used systemically
although these compounds may not be appropriate
for certain in-vitro studies such as determination of
transporter- or receptor-binding aﬃnites. Because
diethyl ether and ethanol have protons, they can be
readily detected by proton NMR. In the case of
paroxetine, the HCl salt forms with a 2:1 ratio of
molecules of paroxetine HCl to molecules of water,
and this hemihydrate must be taken into account
when calculating the theoretical percentages of C, H
and N.
The simple organic extraction procedure described
here provides an economical method to obtain anti-
depressant drugs suitable for use in preclinical re-
search studies from their pharmaceutical preparations.
The antidepressants sertraline, paroxetine, ﬂuoxetine,
venlafaxine, citalopram, escitalopram, duloxetine and
atomoxetine were obtained in moderate to excellent
yield (53–100%) in over 99% purity by elemental
analysis and proton NMR. This method is expected to
be readily applicable to obtaining a variety of other
drugs from their pharmaceutical formulations.
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